Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Overview of Harrow Health Inc.
Harrow Health Inc. (NASDAQ: HROW) is a U.S.-based pharmaceutical company specializing in the development, production, and commercialization of medications that address unmet medical needs. The company’s primary focus lies in ophthalmology, where it provides a comprehensive range of sterile and non-sterile compounded medications, as well as innovative therapeutics for ocular surface diseases and conscious sedation solutions. By targeting specific, often underserved medical needs, Harrow Health plays a critical role in advancing eye care and improving patient outcomes.
Core Business Areas
Harrow Health’s business model is centered on the development and distribution of specialized pharmaceutical products. Its portfolio includes:
- Ophthalmology-Based Formulations: The company offers a variety of compounded medications and topical eye drop drug candidates designed to treat conditions such as dry eye disease (DED) and other ocular surface pathologies.
- Therapeutics for Ocular Surface Diseases: Products like Klarity Drops and oral capsules such as SURF-300 aim to protect and rehabilitate the ocular surface, addressing both the signs and symptoms of DED.
- Sedation and Anesthesia Solutions: Harrow Health develops non-intravenous sedation and anesthesia therapeutics, such as MELT-100, which is administered sublingually for conscious sedation during procedures like cataract surgery.
This diversified portfolio reflects the company’s commitment to addressing complex medical needs through specialized pharmaceutical solutions.
Market Position and Differentiation
Harrow Health operates within the highly specialized ophthalmology segment of the pharmaceutical industry. Its focus on compounded medications and targeted therapeutics allows it to serve niche markets that are often overlooked by larger pharmaceutical companies. By prioritizing accessibility and affordability, Harrow Health ensures that its products reach a broad spectrum of patients and healthcare providers. This approach not only strengthens its market position but also differentiates it from competitors with more generalized portfolios.
Revenue Model and Distribution
The company generates revenue through direct sales to healthcare providers and patients, leveraging a vertically integrated model that encompasses development, production, and distribution. This streamlined approach enables Harrow Health to maintain control over quality and cost, further enhancing its value proposition. Its distribution channels are tailored to meet the needs of U.S.-based eyecare professionals, ensuring timely and efficient delivery of its products.
Challenges and Opportunities
Operating in the pharmaceutical industry, Harrow Health faces challenges such as stringent regulatory requirements, the need for continuous innovation, and competition from both specialized and general pharmaceutical firms. However, its focus on underserved medical needs and its expertise in ophthalmology provide significant opportunities for growth and market penetration. By addressing these challenges effectively, the company is well-positioned to maintain its role as a key player in the ophthalmology sector.
Conclusion
Harrow Health Inc. stands out as a specialized pharmaceutical company dedicated to advancing eye care through innovative and accessible solutions. Its focus on ophthalmology, coupled with a robust portfolio of medications and therapeutics, underscores its commitment to addressing unmet medical needs. By leveraging its expertise and maintaining a patient-centric approach, Harrow Health continues to play a vital role in the U.S. healthcare landscape.
Melt Pharmaceuticals announces the appointment of Brad Osborne as Chief Financial Officer, bringing over 20 years of finance experience, including a decade at Precigen. His expertise spans IPOs, M&A, and SEC compliance. Dr. Larry Dillaha, CEO, emphasizes Osborne's significant role in guiding the company through its ongoing Phase 2 efficacy study for MELT-300 and advancing their patented MELT technology. Melt focuses on non-intravenous and non-opioid sedation solutions, carved out from Harrow Health in 2019, catering to over 100 million medical procedures in the U.S.
Harrow Health (NASDAQ: HROW), an ophthalmic healthcare company, will report its financial results for Q4 and the full year 2021 on March 10, 2022, after market close. A conference call is scheduled for 4:45 p.m. ET the same day to discuss results and provide business updates. Investors can access the Letter to Stockholders on the company's website following the earnings release. Harrow Health focuses on ophthalmic pharmaceuticals through its subsidiaries, ImprimisRx and Visionology.
Harrow Health, Inc. (Nasdaq: HROW) announced that the FDA has accepted its New Drug Application (NDA) for AMP-100, aimed at ocular surface anesthesia. The application has a PDUFA date of October 16, 2022.
CEO Mark L. Baum emphasized that if approved, AMP-100 would be the first non-opioid ophthalmic drug of its kind in the U.S. Harrow Health is committed to making this innovative drug commercially available to ophthalmologists and surgery centers nationwide.
Harrow Health, Inc. (NASDAQ: HROW), a healthcare company focused on ophthalmology, announced that CEO Mark L. Baum and CFO Andrew Boll will present at the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Their presentation is scheduled for February 24, 2022, at 3:30 p.m. ET. To view the presentation, attendees can access the link on Harrow Health's website in the events section. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.
Harrow Health, Inc. (NASDAQ: HROW) has released its inaugural 2022 Corporate Transparency Report, emphasizing its commitment to making sight-saving medications accessible. CEO Mark L. Baum highlights sustainable business practices aimed at benefiting customers and communities. The report details the company’s dedication to innovation, quality, and ethical standards while maintaining strong corporate governance. Harrow Health operates ImprimisRx and Visionology, and holds equity positions in affiliated companies. The report is available in the Investors section of the company’s website.
NASHVILLE, Tenn. -- Harrow Health (NASDAQ: HROW) announced participation in the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Mark L. Baum and CFO Andrew Boll will represent the company. A pre-recorded presentation will be available on Harrow's investor relations website starting January 10 at 7:00 a.m. ET, remaining accessible for 90 days. Harrow Health specializes in ophthalmic healthcare and operates ImprimisRx and Visionology, focusing on innovative eye care solutions.
Melt Pharmaceuticals announced the filing of two INDs with the FDA for non-opioid formulations MELT-210 and MELT-400. The company is actively dosing patients for its Phase 2 pivotal efficacy study of MELT-300, which is expected to complete enrollment by early Q2 2022. MELT-300 offers a needle-free, opioid-free alternative for sedation during cataract surgeries, potentially eliminating the need for opioids and contributing to addressing the opioid crisis. Top-line results are anticipated by the end of Q2 2022.
Harrow Health (NASDAQ: HROW) announced the acquisition of U.S. commercialization rights for four FDA-approved ophthalmic medications from Novartis for $14 million. The products include IOPIDINE®, MAXITROL®, and MOXEZA®, which will enhance Harrow's portfolio in the ophthalmic surgical and acute care markets. This acquisition positions Harrow as a unique provider of both branded products and compounded formulations in the U.S. market, leveraging its ImprimisRx platform for distribution.
Harrow Health, Inc. (Nasdaq: HROW) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective December 20, 2021. This inclusion is a recognition of the company's performance among biotechnology and pharmaceutical securities. CEO Mark L. Baum expressed pride in this milestone, viewing it as validation of the team's efforts to create value for stakeholders. Harrow Health focuses on ophthalmic healthcare, operating ImprimisRx and Visionology, and has interests in other pharmaceuticals. The company aims to provide innovative and affordable eye care solutions.
Harrow Health reports record revenues of $18.7 million for Q3 2021, marking a 30% increase from $14.4 million in the same period last year. The company maintains a gross margin of 74% and achieved commissions from DEXYCU® sales of $900,000. Harrow acquired two FDA drug candidates, AMP-100 and MAQ-100, aiming to enhance its product offerings. Cash and cash equivalents stood at $57.9 million as of September 30, 2021. CEO Mark L. Baum emphasized strong revenue growth, despite challenges posed by COVID-19.
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
What does Harrow Health Inc. specialize in?
How does Harrow Health generate revenue?
What are some key products in Harrow Health’s portfolio?
What sets Harrow Health apart from competitors?
What challenges does Harrow Health face in its industry?
What is Harrow Health’s target market?
Does Harrow Health develop its products in-house?
What types of diseases does Harrow Health address?
